As a leading orphan drug accelerator, Cydan is trusted for our commitment to patients and our understanding of the science. Our expertise in drug development and track record in companies advancing rare disease therapies are utilized in establishing a pipeline of transformative therapies that will make a difference for patients with rare diseases.
Patients and families who live with rare diseases are our focus. According to the National Organization of Rare Diseases (NORD), there are 30 million people in the United States and 350 million people in the world who suffer from a rare disease. Many of these patients find support and information from the patient advocacy groups which have been established. We share common goals with these groups and value our relationships with them.
Our drug development partners are the originators of compelling science and potential rare genetic disease therapies on which we collaborate together to develop. We engage worldwide with academic and government laboratories, small biotechnology and pharmaceutical companies to pinpoint opportunities.
Cydan also seeks out entrepreneurs who work with us on our programs, and then potentially join as the leaders of our new rare disease companies advancing these therapies through clinical development in patients.